Novo Nordisk partners to improve medicine costs for diabetics in USA

Danish diabetes care giant Novo Nordisk (NOV: N) is collaborating with Sempre Health on a pilot program to add diabetes medications to the Sempre affordability and engagement solution.

Unlike traditional coupons and vouchers, Sempre works with health plans to reward their membership's positive choices and actions. For example, a patient may earn a lower co-pay if he/she fills their prescription on time.

The two companies are seeking to engage 10,000 patients with diabetes on the Sempre Health platform in 2018.